Researchers from The University of Texas MD Anderson Cancer Center will present breakthrough studies at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Preliminary clinical results of the MYTHIC study will be presented, revealing for the first time data of the combination of WEE1 and PKMYT1 inhibition (zedoresertib and lunresertib) for the treatment ...
Revolune GmbH, a life science company focused on simplifying spatial biology through streamlined multiplex immunofluorescence (mIF) reagents, today announced it will exhibit at the American ...
The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized oncology. However, a significant proportion of patients ...
At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next?generation sequencing (NGS) typing. These latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results